Related references
Note: Only part of the references are listed.Phase 1 study of mTORC1/2 inhibitor sapanisertib (TAK-228) in advanced solid tumours, with an expansion phase in renal, endometrial or bladder cancer
Martin H. Voss et al.
BRITISH JOURNAL OF CANCER (2020)
Fulvestrant Plus Vistusertib vs Fulvestrant Plus Everolimus vs Fulvestrant Alone for Women With Hormone Receptor-Positive Metastatic Breast Cancer The MANTA Phase 2 Randomized Clinical Trial
Peter Schmid et al.
JAMA ONCOLOGY (2019)
Efficacy of Palbociclib Combinations in Hormone Receptor-Positive Metastatic Breast Cancer Patients After Prior Everolimus Treatment
Ajay Dhakal et al.
CLINICAL BREAST CANCER (2018)
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial
Angelo Di Leo et al.
LANCET ONCOLOGY (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
A Patient-derived Xenograft Model of Pancreatic Neuroendocrine Tumors Identifies Sapanisertib as a Possible New Treatment for Everolimus-resistant Tumors
Chester E. Chamberlain et al.
MOLECULAR CANCER THERAPEUTICS (2018)
Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways
Ji Yeon Son et al.
CANCER MEDICINE (2018)
Phase I study of the investigational oral mTORC1/2 inhibitor sapanisertib (TAK-228): tolerability and food effects of a milled formulation in patients with advanced solid tumours
Kathleen N. Moore et al.
ESMO OPEN (2018)
Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis
Meghan Morrison Joly et al.
BREAST CANCER RESEARCH (2017)
TAK-228 (formerly MLN0128), an investigational oral dual TORC1/2 inhibitor: A phase I dose escalation study in patients with relapsed or refractory multiple myeloma, non-Hodgkin lymphoma, or Waldenstrom's macroglobulinemia
Irene M. Ghobrial et al.
AMERICAN JOURNAL OF HEMATOLOGY (2016)
Mutation of genes of the PI3K/AKT pathway in breast cancer supports their potential importance as biomarker for breast cancer aggressiveness
Aggeliki Tserga et al.
VIRCHOWS ARCHIV (2016)
MLN0128, a novel mTOR kinase inhibitor, disrupts survival signaling and triggers apoptosis in AML and AML stem/progenitor cells
Zhihong Zeng et al.
ONCOTARGET (2016)
Biological subtypes of breast cancer: Prognostic and therapeutic implications
Ozlem Yersal et al.
WORLD JOURNAL OF CLINICAL ONCOLOGY (2014)
Endocrine Resistance in Breast Cancer: Focus on the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Pathway
Shira Peleg Hasson et al.
BREAST CARE (2013)
Improving Endocrine Therapy for Breast Cancer: It's Not That Simple
E. Claire Dees et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Endocrine therapy: is the first generation of targeted drugs the last?
K. I. Pritchard
JOURNAL OF INTERNAL MEDICINE (2013)
A phase 1, dose-escalation study of MLN0128, an investigational oral mammalian target of rapamycin complex 1/2 (mTORC1/2) catalytic inhibitor, in patients (pts) with advanced non-hematologic malignancies
Jeffrey R. Infante et al.
MOLECULAR CANCER THERAPEUTICS (2013)
Investigational drug MLN0128, a novel TORC1/2 inhibitor, demonstrates potent oral antitumor activity in human breast cancer xenograft models
Yesim Goekmen-Polar et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
Naifa L. Busaidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The translational landscape of mTOR signalling steers cancer initiation and metastasis
Andrew C. Hsieh et al.
NATURE (2012)
Phosphatidylinositol 3-Kinase and Antiestrogen Resistance in Breast Cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer
Todd W. Miller et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors
Josep Tabernero et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Mechanisms of acquired resistance to endocrine therapy in hormone-dependent breast cancer cells
Wei Yue et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2007)
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt
KE O'Reilly et al.
CANCER RESEARCH (2006)
Adaptive hypersensitivity to estrogen: Mechanisms and clinical relevance to aromatase inhibitor therapy in breast cancer treatment
RJ Santen et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Molecular portraits of human breast tumours
CM Perou et al.
NATURE (2000)
Share Paper
